pta Search Results


l reuteri atcc pta 6475  (ATCC)
96
ATCC l reuteri atcc pta 6475
Limosilactobacillus reuteri DSM 17938 + ATCC <t>PTA</t> <t>6475</t> and improvement on irritable bowel syndrome symptoms.
L Reuteri Atcc Pta 6475, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/l reuteri atcc pta 6475/product/ATCC
Average 96 stars, based on 1 article reviews
l reuteri atcc pta 6475 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
pe cd226  (Miltenyi Biotec)
93
Miltenyi Biotec pe cd226
Limosilactobacillus reuteri DSM 17938 + ATCC <t>PTA</t> <t>6475</t> and improvement on irritable bowel syndrome symptoms.
Pe Cd226, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe cd226/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
pe cd226 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
atcc accession numbers pta 2792  (ATCC)
97
ATCC atcc accession numbers pta 2792
Limosilactobacillus reuteri DSM 17938 + ATCC <t>PTA</t> <t>6475</t> and improvement on irritable bowel syndrome symptoms.
Atcc Accession Numbers Pta 2792, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atcc accession numbers pta 2792/product/ATCC
Average 97 stars, based on 1 article reviews
atcc accession numbers pta 2792 - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
lapc 4 cells  (ATCC)
96
ATCC lapc 4 cells
Limosilactobacillus reuteri DSM 17938 + ATCC <t>PTA</t> <t>6475</t> and improvement on irritable bowel syndrome symptoms.
Lapc 4 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lapc 4 cells/product/ATCC
Average 96 stars, based on 1 article reviews
lapc 4 cells - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
cd226 vioblue  (Miltenyi Biotec)
94
Miltenyi Biotec cd226 vioblue
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Cd226 Vioblue, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd226 vioblue/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd226 vioblue - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
atcc repository  (ATCC)
95
ATCC atcc repository
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Atcc Repository, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atcc repository/product/ATCC
Average 95 stars, based on 1 article reviews
atcc repository - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
그람음성균의 하나인 e coli dh5α  (ATCC)
96
ATCC 그람음성균의 하나인 e coli dh5α
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
그람음성균의 하나인 E Coli Dh5α, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/그람음성균의 하나인 e coli dh5α/product/ATCC
Average 96 stars, based on 1 article reviews
그람음성균의 하나인 e coli dh5α - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
f11bab  (ATCC)
94
ATCC f11bab
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
F11bab, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/f11bab/product/ATCC
Average 94 stars, based on 1 article reviews
f11bab - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
human prostate cancer cells  (ATCC)
95
ATCC human prostate cancer cells
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Human Prostate Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human prostate cancer cells/product/ATCC
Average 95 stars, based on 1 article reviews
human prostate cancer cells - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
yersinia enterocolitica atcc  (ATCC)
95
ATCC yersinia enterocolitica atcc
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Yersinia Enterocolitica Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/yersinia enterocolitica atcc/product/ATCC
Average 95 stars, based on 1 article reviews
yersinia enterocolitica atcc - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
l reuteri atcc pta 5289  (ATCC)
96
ATCC l reuteri atcc pta 5289
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
L Reuteri Atcc Pta 5289, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/l reuteri atcc pta 5289/product/ATCC
Average 96 stars, based on 1 article reviews
l reuteri atcc pta 5289 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
campylobacter jejuni atcc 29428  (ATCC)
96
ATCC campylobacter jejuni atcc 29428
Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and <t>CD226</t> expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).
Campylobacter Jejuni Atcc 29428, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/campylobacter jejuni atcc 29428/product/ATCC
Average 96 stars, based on 1 article reviews
campylobacter jejuni atcc 29428 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

Image Search Results


Limosilactobacillus reuteri DSM 17938 + ATCC PTA 6475 and improvement on irritable bowel syndrome symptoms.

Journal: Frontiers in Gastroenterology

Article Title: Limosilactobacillus reuteri DSM 17938 and ATCC PTA 6475 for the treatment of moderate to severe irritable bowel syndrome in adults: a randomized controlled trial

doi: 10.3389/fgstr.2023.1296048

Figure Lengend Snippet: Limosilactobacillus reuteri DSM 17938 + ATCC PTA 6475 and improvement on irritable bowel syndrome symptoms.

Article Snippet: Limosilactobacillus reuteri DSM 17938 and L. reuteri ATCC PTA 6475 are two strains of L. reuteri species, with specific modes of action as identified in vitro and in animal models, showing clear anti-inflammatory potential as well as intestinal epithelial integrity and gut homeostasis capabilities.

Techniques:

Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and CD226 expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).

Journal: Cancers

Article Title: Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

doi: 10.3390/cancers15030904

Figure Lengend Snippet: Impact of chemotherapy on percentage of ( A ) cytotoxic NK cells of lymphocytes and NK-cell-specific activating receptors. ( B – E ) 5 × 10 6 PBMCs were treated for 24 h under cell culture conditions with either carboplatin (2 µg/mL, open circles), cisplatin (1 µg/mL, open triangles), etoposide (0.5 µg/mL, open squares), vincristine (0.05 µg/mL, open diamonds), or the cyclophosphamide metabolite (4-HPC, 1 µg/mL, open hexagons). After 72 h of culturing, cells were analyzed for NKp30, NKp44, NKp46, NKG2D, and CD226 expression, using flow cytometry. ( A ) Relative number of cytotoxic NK cells (CD3 − , CD56 dim ) in lymphocytes. ( B – E ) Geometric mean fluorescence intensity (gMFI) of respective activating receptor of cytotoxic NK cells after chemotherapy. Data represent at least four biological replicates. Means and SEM are indicated as black lines and error bars, respectively. For statistical analysis, repeated measures ANOVA with appropriate post hoc test was used; * p < 0.05 vs., ** p < 0.01 versus untreated control (medium).

Article Snippet: Incubation with the following antibodies in a total volume of 100 μL was conducted for 20 min at RT: CD3-VioGreen (REA613, 1:200), CD56-APC-Vio770 (REA196, 1:200), CD226-VioBlue (REA1040, 1:50); CD335 (NKp46)-Vio Bright B515 (REA808, 1:50), CD337 (NKp30)-PE (REA823, 1:75), CD336 (NKp44)-APC (REA1163, 1:75), and CD314 (NKG2D)-PE-Vio 770 (REA1228, 1:75), all from Miltenyi Biotec.

Techniques: Cell Culture, Expressing, Flow Cytometry, Fluorescence, Control